Skip to main content Accessibility help
×
Home
  • Print publication year: 2000
  • Online publication date: May 2017

Chapter 12 - Prevention of Acute Graft-versus-Host Disease − One Size Fits All?

from Section 4 - Early Post-Transplant Interval

Related content

Powered by UNSILO
1.Barrett, AJ, Le Blanc, K. Prophylaxis of acute GVHD: manipulate the graft or the environment? Best Practice & Research Clinical Haematology. 2008;21(2):165–76.
2.Wysocki, CA, Panoskaltsis-Mortari, A, Blazar, BR, Serody, JS. Leukocyte migration and graft-versus-host disease. Blood. 2005;105(11):4191–9.
3.Goker, H, Haznedaroglu, IC, Chao, NJ. Acute graft-vs-host disease: pathobiology and management. Experimental Hematology. 2001;29(3):259–77.
4.Alousi, AM, Bolanos-Meade, J, Lee, SJ. Graft-versus-host disease: state of the science. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2013;19(1 Suppl):S102–8.
5.Al-Kadhimi, Z, Gul, Z, Chen, W, Smith, D, Abidi, M, Deol, A, et al. High incidence of severe acute graft-versus-host disease with tacrolimus and mycophenolate mofetil in a large cohort of related and unrelated allogeneic transplantation patients. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2014;20(7):979–85.
6.Sung, AD, Chao, NJ. Acute graft-versus-host disease: are we close to bringing the bench to the bedside? Best Practice & Research Clinical Haematology. 2013;26(3):285–92.
7.Ferrara, JL, Levine, JE, Reddy, P, Holler, E. Graft-versus-host disease. Lancet. 2009;373(9674):1550–61.
8.Ruutu, T, van Biezen, A, Hertenstein, B, Henseler, A, Garderet, L, Passweg, J, et al. Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation. 2012;47(11):1459–64.
9.Hamad, N, Del Bel, R, Messner, HA, Kim, D, Kuruvilla, J, Lipton, JH, et al. Outcomes of hematopoietic cell transplantation in adult patients with acquired aplastic anemia using intermediate dose alemtuzumab-based conditioning. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2014;20(11):1722–8.
10.Kanda, J, Long, GD, Gasparetto, C, Horwitz, ME, Sullivan, KM, Chute, JP, et al. Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2014;20(2):257–63.
11.Grullich, C, Ziegler, C, Finke, J. Rabbit anti T-lymphocyte globulin induces apoptosis in peripheral blood mononuclear cell compartments and leukemia cells, while hematopoetic stem cells are apoptosis resistant. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2009;15(2):173–82.
12.Bacigalupo, A, Lamparelli, T, Bruzzi, P, Guidi, S, Alessandrino, PE, di Bartolomeo, P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001;98(10):2942–7.
13.Finke, J, Bethge, WA, Schmoor, C, Ottinger, HD, Stelljes, M, Zander, AR, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. The Lancet Oncology. 2009;10(9):855–64.
14.Soiffer, RJ, Lerademacher, J, Ho, V, Kan, F, Artz, A, Champlin, RE, et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood. 2011;117(25):6963–70.
15.Theurich, S, Fischmann, H, Shimabukuro-Vornhagen, A, Chemnitz, JM, Holtick, U, Scheid, C, et al. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults. The Cochrane Database of Systematic Reviews. 2012;9:CD009159.
16.Luznik, L, Bolanos-Meade, J, Zahurak, M, Chen, AR, Smith, BD, Brodsky, R, et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010;115(16):3224–30.
17.Luznik, L, O’Donnell, PV, Symons, HJ, Chen, AR, Leffell, MS, Zahurak, M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2008;14(6):641–50.
18.Reshef, R, Luger, SM, Hexner, EO, Loren, AW, Frey, NV, Nasta, SD, et al. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. The New England Journal of Medicine. 2012;367(2):135–45.
19.Ram, R, Storb, R. Pharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future. Leukemia & Lymphoma. 2013;54(8):1591–601.
20.Koreth, J, Stevenson, KE, Kim, HT, McDonough, SM, Bindra, B, Armand, P, et al. Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2012;30(26):3202–8.
21.Kraut, EH, Neff, JC, Bouroncle, BA, Gochnour, D, Grever, MR. Immunosuppressive effects of pentostatin. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 1990;8(5):848–55.
22.Parmar, S, Andersson, BS, Couriel, D, Munsell, MF, Fernandez-Vina, M, Jones, RB, et al. Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2011;29(3):294302.
23.Dinarello, CA, Fossati, G, Mascagni, P. Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer. Molecular Medicine. 2011;17(5–6):333–52.
24.Choi, SW, Braun, T, Chang, L, Ferrara, JL, Pawarode, A, Magenau, JM, et al. Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. The Lancet Oncology. 2014;15(1):8795.
25.Zeiser, R, Youssef, S, Baker, J, Kambham, N, Steinman, L, Negrin, RS. Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. Blood. 2007;110(13):4588–98.
26.Hamadani, M, Gibson, LF, Remick, SC, Wen, S, Petros, W, Tse, W, et al. Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2013;31(35):4416–23.
27.Pillai, AB, George, TI, Dutt, S, Strober, S. Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease. Blood. 2009;113(18):4458–67.
28.Lowsky, R, Takahashi, T, Liu, YP, Dejbakhsh-Jones, S, Grumet, FC, Shizuru, JA, et al. Protective conditioning for acute graft-versus-host disease. The New England Journal of Medicine. 2005;353(13):1321–31.
29.Kohrt, HE, Turnbull, BB, Heydari, K, Shizuru, JA, Laport, GG, Miklos, DB, et al. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood. 2009;114(5):1099–109.
30.Messina, G, Giaccone, L, Festuccia, M, Irrera, G, Scortechini, I, Sorasio, R, et al. Multicenter experience using total lymphoid irradiation and antithymocyte globulin as conditioning for allografting in hematological malignancies. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2012;18(10):1600–7.
31.Ringden, O, Pihlstedt, P, Markling, L, Aschan, J, Baryd, I, Ljungman, P, et al. Prevention of graft-versus-host disease with T-cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients. Bone Marrow Transplantation. 1991;7(3):221–6.
32.Wagner, JE, Thompson, JS, Carter, SL, Kernan, NA, members of the Unrelated Donor Marrow Transplantation Trial. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet. 2005;366(9487):733–41.
33.Pavletic, SZ, Carter, SL, Kernan, NA, Henslee-Downey, J, Mendizabal, AM, Papadopoulos, E, et al. Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood. 2005;106(9):3308–13.
34.Pasquini, MC, Devine, S, Mendizabal, A, Baden, LR, Wingard, JR, Lazarus, HM, et al. Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2012;30(26):3194–201.
35.Cutler, C, Logan, B, Nakamura, R, Johnston, L, Choi, S, Porter, D, et al. Tacrolimus/sirolimus versus tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic hematopoietic cell transplantation. Blood. 2014;124(8):1372–7.